Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report issued on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance NASDAQ AKTX opened at $0.21 on Tuesday. Akari Therapeutics has a 52 week low of $0.14 and a 52 week high of […]